Progress Soft SEC Filings

Oxford Square Capital Corp. has filed a Definitive Additional Proxy Material (DEFA14A) to notify stockholders of the 2025 Annual Meeting scheduled for 9:00 a.m. ET on August 20, 2025 at the company’s headquarters in Greenwich, CT. The filing outlines the Notice & Access model, directing investors to https://www.proxy-direct.com/oxf-34572 for full proxy materials or to request paper copies by August 8, 2025. Shareholders will vote on two routine proposals:

• Election of one director—Barry A. Osherow—to serve until the 2028 Annual Meeting.
• Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.

Voting can be completed online, by telephone, or via mailed proxy upon request using the provided 14-digit Control Number and 8-digit Security Code. The company reserves the right to switch to a virtual format, with any change to be announced via additional proxy materials and press release. No filing fee is required for this submission.

Form 4 filing overview: On 07/02/2025, Zai Lab Ltd (ticker: ZLAB) granted its Chairperson & Chief Executive Officer, Du Ying, a new equity award in the form of 44,194 Restricted Share Units (RSUs). Each RSU converts into one American Depositary Share (ADS), and every ADS represents ten ordinary shares of the company.

Key terms of the award:

• Vesting schedule: The RSUs vest in four equal annual tranches starting 07/02/2026 and ending 07/02/2029, contingent on continued service.
• Cost basis: The grant price is reported as $0 because RSUs are awarded, not purchased.
• Post-grant holdings: The filing shows 44,194 derivative securities (RSUs) beneficially owned directly by the reporting person after the transaction; no common ADS transactions were reported in Table I.

Investor takeaways: The award is a routine incentive grant that aligns top-management compensation with shareholder value creation over a multi-year horizon. There is no indication of share sales or disposals, so the transaction does not reflect profit-taking or a change in ownership intent. While the grant reinforces long-term alignment, it has no immediate cash flow or earnings impact and is unlikely to materially move the stock on its own.

Form 4 filing overview: On 07/02/2025, Zai Lab Ltd (ticker: ZLAB) granted its Chairperson & Chief Executive Officer, Du Ying, a new equity award in the form of 44,194 Restricted Share Units (RSUs). Each RSU converts into one American Depositary Share (ADS), and every ADS represents ten ordinary shares of the company.

Key terms of the award:

• Vesting schedule: The RSUs vest in four equal annual tranches starting 07/02/2026 and ending 07/02/2029, contingent on continued service.
• Cost basis: The grant price is reported as $0 because RSUs are awarded, not purchased.
• Post-grant holdings: The filing shows 44,194 derivative securities (RSUs) beneficially owned directly by the reporting person after the transaction; no common ADS transactions were reported in Table I.

Investor takeaways: The award is a routine incentive grant that aligns top-management compensation with shareholder value creation over a multi-year horizon. There is no indication of share sales or disposals, so the transaction does not reflect profit-taking or a change in ownership intent. While the grant reinforces long-term alignment, it has no immediate cash flow or earnings impact and is unlikely to materially move the stock on its own.

Bank of Montreal (BMO) is offering auto-callable Market Linked Securities tied to the lowest performing share among Advanced Micro Devices (AMD), Amazon.com (AMZN) and Alphabet Class A (GOOGL). Each security has a $1,000 face amount, will be priced on July 18 2025 and issued on July 23 2025.

Early call feature: if on the July 23 2026 call date the lowest-performing Underlier closes at or above 90 % of its starting value, the notes are automatically redeemed for $1,000 plus a call premium of at least 25.35 %. Investors then forgo all further upside.

At maturity (July 21 2028) if not called:

• Upside: 200 % participation in any gain of the worst Underlier.
• Contingent absolute return: if that Underlier ends ≤ its start but ≥ 55 %, holders receive a positive payout equal to the absolute decline (maximum 45 %).
• Downside: if it finishes below 55 %, investors are fully exposed to the loss and can lose up to 100 % of principal.

Bank of Montreal (BMO) is offering auto-callable Market Linked Securities tied to the lowest performing share among Advanced Micro Devices (AMD), Amazon.com (AMZN) and Alphabet Class A (GOOGL). Each security has a $1,000 face amount, will be priced on July 18 2025 and issued on July 23 2025.

Early call feature: if on the July 23 2026 call date the lowest-performing Underlier closes at or above 90 % of its starting value, the notes are automatically redeemed for $1,000 plus a call premium of at least 25.35 %. Investors then forgo all further upside.

At maturity (July 21 2028) if not called:

• Upside: 200 % participation in any gain of the worst Underlier.
• Contingent absolute return: if that Underlier ends ≤ its start but ≥ 55 %, holders receive a positive payout equal to the absolute decline (maximum 45 %).
• Downside: if it finishes below 55 %, investors are fully exposed to the loss and can lose up to 100 % of principal.

Bank of Montreal (BMO) is offering auto-callable Market Linked Securities tied to the lowest performing share among Advanced Micro Devices (AMD), Amazon.com (AMZN) and Alphabet Class A (GOOGL). Each security has a $1,000 face amount, will be priced on July 18 2025 and issued on July 23 2025.

Early call feature: if on the July 23 2026 call date the lowest-performing Underlier closes at or above 90 % of its starting value, the notes are automatically redeemed for $1,000 plus a call premium of at least 25.35 %. Investors then forgo all further upside.

At maturity (July 21 2028) if not called:

• Upside: 200 % participation in any gain of the worst Underlier.
• Contingent absolute return: if that Underlier ends ≤ its start but ≥ 55 %, holders receive a positive payout equal to the absolute decline (maximum 45 %).
• Downside: if it finishes below 55 %, investors are fully exposed to the loss and can lose up to 100 % of principal.

Bank of Montreal (BMO) is offering auto-callable Market Linked Securities tied to the lowest performing share among Advanced Micro Devices (AMD), Amazon.com (AMZN) and Alphabet Class A (GOOGL). Each security has a $1,000 face amount, will be priced on July 18 2025 and issued on July 23 2025.

Early call feature: if on the July 23 2026 call date the lowest-performing Underlier closes at or above 90 % of its starting value, the notes are automatically redeemed for $1,000 plus a call premium of at least 25.35 %. Investors then forgo all further upside.

At maturity (July 21 2028) if not called:

• Upside: 200 % participation in any gain of the worst Underlier.
• Contingent absolute return: if that Underlier ends ≤ its start but ≥ 55 %, holders receive a positive payout equal to the absolute decline (maximum 45 %).
• Downside: if it finishes below 55 %, investors are fully exposed to the loss and can lose up to 100 % of principal.

Tectonic Therapeutic, Inc. (Nasdaq: TECX) has filed a Form S-3 shelf registration that allows the company to issue up to $400 million of common stock, preferred stock, debt securities and/or warrants. The filing also includes a dedicated $100 million at-the-market (ATM) sales agreement with TD Securities (USA) LLC, giving management flexibility to raise capital "from time to time" as clinical milestones approach.

The prospectus reiterates Tectonic’s strategy of developing biologics that modulate GPCRs via its proprietary GEODe™ platform. Lead asset TX45 (Fc-relaxin fusion) has completed a Phase 1a study showing good tolerability and a favourable PK/PD profile. In Part A of an ongoing Phase 1b hemodynamic trial in PH-HFpEF patients, TX45 achieved a 19% reduction in pulmonary capillary wedge pressure and a >30% PVR reduction in a severe sub-population, with no serious adverse events. Recruitment is under way for Part B (PH-HFrEF), and the 24-week placebo-controlled Phase 2 APEX trial dosed its first patient in October 2024; topline data are expected in 2026.

Second program TX2100, a VHH-Fc fusion for Hereditary Hemorrhagic Telangiectasia, entered IND-enabling studies in Q2 2025, with a Phase 1 start targeted for late 2025/early 2026. The company completed a reverse-merger with Legacy Tectonic in June 2024 and now qualifies as a smaller reporting company. Proceeds from any sales under the shelf will fund pipeline advancement, working capital and potential in-licensing.

As of 3 July 2025 the stock traded at $21.34 per share. While the registration itself is not a financing event, it signals possible future dilution balanced by improved funding optionality ahead of multiple clinical catalysts.

Tectonic Therapeutic, Inc. (Nasdaq: TECX) has filed a Form S-3 shelf registration that allows the company to issue up to $400 million of common stock, preferred stock, debt securities and/or warrants. The filing also includes a dedicated $100 million at-the-market (ATM) sales agreement with TD Securities (USA) LLC, giving management flexibility to raise capital "from time to time" as clinical milestones approach.

The prospectus reiterates Tectonic’s strategy of developing biologics that modulate GPCRs via its proprietary GEODe™ platform. Lead asset TX45 (Fc-relaxin fusion) has completed a Phase 1a study showing good tolerability and a favourable PK/PD profile. In Part A of an ongoing Phase 1b hemodynamic trial in PH-HFpEF patients, TX45 achieved a 19% reduction in pulmonary capillary wedge pressure and a >30% PVR reduction in a severe sub-population, with no serious adverse events. Recruitment is under way for Part B (PH-HFrEF), and the 24-week placebo-controlled Phase 2 APEX trial dosed its first patient in October 2024; topline data are expected in 2026.

Second program TX2100, a VHH-Fc fusion for Hereditary Hemorrhagic Telangiectasia, entered IND-enabling studies in Q2 2025, with a Phase 1 start targeted for late 2025/early 2026. The company completed a reverse-merger with Legacy Tectonic in June 2024 and now qualifies as a smaller reporting company. Proceeds from any sales under the shelf will fund pipeline advancement, working capital and potential in-licensing.

As of 3 July 2025 the stock traded at $21.34 per share. While the registration itself is not a financing event, it signals possible future dilution balanced by improved funding optionality ahead of multiple clinical catalysts.